Hepatitis B virus-persistent infection and innate immunity defect: Cell-related or virus-related?
Hepatitis B virus-persistent infection and innate immunity defect: Cell-related or virus-related?
复制标题
DOI：
10.12998/wjcc.v6.i9.233
复制
发表时间：
2018-09-06
影响因子：
1.1
通讯作者：
Gong GZ
中科院分区：
文献类型：
--
作者：
Tang J;Wu ZY;Dai RJ;Ma J;Gong GZ
乙型肝炎病毒（HBV）感染的结局与获得感染的年龄密切相关。成人感染往往是自我限制的，与围产期感染相反，围产期感染HBV的一般结果是慢性持久性。先天免疫在病毒感染早期起着不可或缺的作用，促进病毒的清除。然而，据报道，在感染的早期阶段，先天免疫系统对HBV的识别和清除不足，这可能解释了病毒血症之后的长期持续。此外，由于共价闭合环状DNA的存在，即使给予干扰素-α和核苷酸/核苷类似物进行抗病毒治疗，慢性HBV清除也非常困难。HBV逃避先天免疫识别并建立持续感染的机制仍然是一个有争议的话题。此外，一些研究人员对如何通过恢复或增强先天免疫来根除慢性HBV感染越来越感兴趣。本综述旨在总结目前关于肝内细胞信号通路和先天免疫细胞在HBV感染发生后的作用以及这些作用与HBV持续存在的关系的知识。我们期望本文提出的见解有助于未来开发新的免疫治疗策略来对抗HBV感染。
The outcomes of hepatitis B virus (HBV) infection are closely related to the age at which infection was acquired. Infection acquired in adult life tends to be self-limited, in contrast to perinatal acquirement, for which chronic persistence of the HBV is a general outcome. Innate immunity plays an indispensable role in early virus infection, facilitating virus clearance. However, it has been reported that HBV is under-recognized and poorly eliminated by the innate immune system in the early stages of infection, possibly explaining the long-lasting persistence of viremia afterwards. Furthermore, due to the existence of covalently closed circular DNA, chronic HBV clearance is very difficult, even when patients are given interferon-α and nucleotide/nucleoside analogs for antiviral therapy. The mechanism by which HBV evades innate immune recognition and establishes persistent infection remains a subject of debate. Besides, some researchers are becoming more interested in how to eradicate chronic HBV infection by restoring or boosting innate immunity. This review aimed to summarize the current knowledge on how intrahepatocyte signaling pathways and innate immune cells act after the onset of HBV infection and how these actions are related to the persistence of HBV. We anticipate the insights presented herein to be helpful for future development of novel immune therapeutic strategies to fight HBV infection.
登录
查看更多内容
影响因子：
64.5
作者：
Dixit E;Boulant S;Zhang Y;Lee AS;Odendall C;Shum B;Hacohen N;Chen ZJ;Whelan SP;Fransen M;Nibert ML;Superti-Furga G;Kagan JC
通讯作者：
Kagan JC
影响因子：
9.1
作者：
Duan, XZ;Wang, M;Wang, FS
通讯作者：
Wang, FS
影响因子：
5.4
作者：
Jegaskanda, S.;Ahn, S. H.;Revill, P. A.
通讯作者：
Revill, P. A.
影响因子：
15.9
作者：
Gehring, Adam J.;Haniffa, Muzlifah;Bertoletti, Antonio
通讯作者：
Bertoletti, Antonio
影响因子：
4.6
作者：
Hou Z;Zhang J;Han Q;Su C;Qu J;Xu D;Zhang C;Tian Z
通讯作者：
Tian Z